|
市場調查報告書
葛雷克氏症治療藥品
Lou Gehrig's Disease
|
葛雷克氏症治療藥品 是由出版商Global Industry Analysts, Inc.在2010年04月所出版的。
這份英文市場調查報告書包含Pages: 258 價格從美金3450起跳。
本報告為，調查分析全球葛雷克氏症（肌萎縮性脊髓側索硬化症）治療藥品市場，並匯整本疾病概要及治療方式、新式治療之開發趨勢、市場參與企業簡介，以下列摘要形式闡述。
第1章 簡介、調查方式、產品定義
第2章 實施概要
- 產業概要
- 全球市場分析
- Sanofi-Aventis：唯一肌萎縮性脊髓側索硬化症藥劑製造商
- Rilutek
- 肌萎縮性脊髓側索硬化症罹患率及病患數
- 肌萎縮性脊髓側索硬化症：概要
- 主要種類
- 病因
- 尚未釐清之肌萎縮性脊髓側索硬化症患病原因
- 診斷
- 肌萎縮性脊髓側索硬化症症狀
- 肌萎縮性脊髓側索硬化症之應變措施
- 治療方式
- 對症治療
- 肌萎縮性脊髓側索硬化症潛力療法
- 神經營養因子
- 小分子
- RNA干擾
- 幹細胞帶來之新希望
- 幹細胞研究
- 製作盧伽雷氏病模式之LTC
- 草藥治療
- 鋰
- 肌萎縮性脊髓側索硬化症基因學
- 臨床實驗及研究
- 近年產業活動
- 主要企業
- Aeolus Pharmaceuticals, Inc.
- Amorfix Life Sciences Ltd.
- Avicena Group, Inc.
- Ceregene, Inc.
- CytRx Corporation
- Genzyme Corporation
- Isis Pharmaceuticals, Inc.
- Knopp Neurosciences
- Maas Biolab
- NeuroNova AB
- Sygnis Pharma AG
- Teva Pharmaceutical Industries Ltd.
- Trophos SA
- 肌萎縮性脊髓側索硬化症相關機構
- 全球市場展望
第3章 競合情況
Abstract
This report analyzes the Global market for Lou Gehrig' s Disease in US$
Million. Annual estimates and forecasts are provided for the period 2006
through 2015. The report profiles 37 companies including many key and niche
players such as Aeolus Pharmaceuticals, Inc., Amorfix Life Sciences Ltd.,
Avicena Group, Inc., Ceregene, Inc., CytRx Corporation, Genzyme Corporation,
Isis Pharmaceuticals, Inc., Knopp Neurosciences, Maas Biolab, NeuroNova AB,
Sygnis Pharma AG, Teva Pharmaceutical Industries Ltd., and Trophos SA. Market
data and analytics are derived from primary and secondary research. Company
profiles are mostly extracted from URL research and reported select online
sources.
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
- Global Market Analysis
- Sanofi-Aventis - The Only Drug Maker for ALS
- Rilutek
- Prevalence and Incidence of ALS
- The United States
- Canada
- Table 1: Mortality Rate of ALS in Canada - A Historic Review (includes
corresponding Graph/Chart)
- The United Kingdom
- New Zealand
- Australia
- Table 2: Mortality Rate in Australia for Years 2005 through 2007(includes
corresponding Graph/Chart)
2. AMYOTROPHIC LATERAL SCLEROSIS - AN INSIGHT
- Major Types of ALS
- Etiology
- Exact Causes of ALS Still Unknown
- Major Milestones in ALS Treatment Arena
- Diagnosis
- Symptoms of ALS
- Initial symptoms
- Emerging Symptoms
- Use of BiPAP, IPPV and Mechanical Respirators in ALS
- Measures to Deal with ALS Problems
- Treatment
- Symptomatic Treatment
3. POTENTIAL THERAPIES FOR ALS
- Neurotrophic Factors
- Insulin-like Growth Factor
- Vascular endothelial growth factor
- Sangamo BioSciences to Develop SB 509
- Smaller Molecules
- RNA Interference
- Stem Cells Offer New Hope
- Studies on Stem Cells
- LTC to Develop New Lou Gehrig' s Disease Models
- Herbal Treatment
- Lithium: A potential Treatment for ALS
- Advancements in ALS Genetics
- Select Pipeline Drugs for ALS Under Clinical Trials (2009)
4. CLINICAL TRIALS AND RESEARCH STUDIES
- CytRx Initiates Phase 2/3 Clinical Trial for Arimoclomol
- New Treatment for ALS Patients
- KNS-760704 Receives Orphan Designation
- KNS-760704 Enters Phase 2 Study
- Maas Biolab SBIR Initiates Phase 2 for Cyclosporin
- Researchers Identify New Gene for ALS
5. RECENT INDUSTRY ACTIVITY
- Merck to Purchase Insmed' s Assets
- NeuroNova Signs Agreement with Genentech
- Insmed Inks a Deal with IDIS to Organize NPPs for IPLEXTM
- Teva to Extend Branded Products in Niche Specialty Diseases
- Asklepios and ALS TDI Develop Latest Therapeutic Delivery Alternatives for
ALS Treatment
- Medicare Extends DME Coverage of HFCWO to Cure Neuromuscular Disorders
- Neuralstem and Hospital of Taiwan Collaborate for Development of Neural
Stem Cell Therapies
- Life Technologies to Create Neurodegenerative Disease Models
- Medicare Extends the Coverage of HFCWO to Cure Neuromuscular Disorders
- Sygnis Obtains Orphan Drug Status for AX200 in Spinal Cord Injury Treatment
- Insmed Obtains Royalty-Free Global Rights for IPLEXTM
- Q Therapeutics Collaborates with Johns Hopkins Research Team
- Aldagen to Collaborate with UC Davis
- ALS TDI Collaborates with CSC
- ALS TDI and Allen Institute for Brain Science Enter into Agreement
- Amorfix Completes Research Partnership with Biogen Idec
- Isis Receives Orphan Drug Designation
- Prize4Life Endorses BrainStorm to Develop ALS Cure
- ALS TDI Selects Microbix to Manufacture Adenoviruses
- Maas BiolAB Receives SBIR Grant
- Neuralstem Collaborates with University of Michigan
- ALS TDI and MDA Collaborate
6. PLAYERS VENTURING THE ALS MARKET
- Aeolus Pharmaceuticals, Inc. (US)
- Amorfix Life Sciences Ltd. (Canada)
- Avicena Group, Inc. (US)
- Ceregene, Inc. (US)
- CytRx Corporation (US)
- Genzyme Corporation (US)
- Isis Pharmaceuticals, Inc. (US)
- Knopp Neurosciences (US)
- Maas Biolab (US)
- NeuroNova AB (Sweden)
- Sygnis Pharma AG (Germany)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Trophos SA (France)
7. ASSOCIATIONS INVOLVED IN ALS RESEARCH
- Northeast Amyotrophic Lateral Sclerosis Consortium (US)
- Muscular Dystrophy Association (MDA)
- The ALS Association
- ALS Society of Canada
- ALS Therapy Development Institute
- Motor Neurone Disease Research Institute of Australia
8. GLOBAL MARKET PERSPECTIVE
- Table 3: World Recent Past, Current & Future Analysis for Lou Gehrig' s
Disease by Geographic Region - US, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart)
- Table 4: World 10-Year Perspective for Lou Gehrig' s Disease by Geographic
Region -Percentage Breakdown of Sales for US, and Rest of World Markets for
Years 2006, 2009 & 2015
III. COMPETITIVE LANDSCAPE
|
